GLP-1 medications are remarkably effective for most people, but they aren't appropriate for everyone. Before prescribing semaglutide or tirzepatide, a responsible provider should screen for several pre-existing conditions that could affect your safety, your treatment plan, or both.
This isn't about gatekeeping. It's about making sure the medication is safe for you specifically — and that your provider has the full picture before writing that prescription.
Absolute Contraindications: When GLP-1s Are Not an Option
These conditions are considered firm contraindications based on FDA labeling and clinical guidelines:
Personal or Family History of Medullary Thyroid Carcinoma (MTC)
Both semaglutide and tirzepatide carry a boxed warning — the FDA's most serious warning — regarding thyroid C-cell tumors. This comes from animal studies in rodents. While the risk in humans hasn't been definitively established, the precautionary principle applies. If you or a first-degree relative (parent, sibling, child) has been diagnosed with medullary thyroid carcinoma, GLP-1 medications are contraindicated.
Multiple Endocrine Neoplasia Syndrome Type 2 (MEN 2)
MEN 2 is a rare genetic condition that increases the risk of medullary thyroid cancer. Patients with MEN 2 should not take GLP-1 receptor agonists. If you have a family history of unusual endocrine tumors, make sure your provider knows.
Known Hypersensitivity
If you've had an allergic reaction to semaglutide, tirzepatide, or any of the inactive ingredients in a specific formulation, that particular medication is off the table. Your provider may be able to switch you to the other class instead (semaglutide to tirzepatide or vice versa).
Conditions That Require Extra Caution
These don't necessarily disqualify you, but they change how your treatment should be managed:
History of Pancreatitis
GLP-1 medications have been associated with cases of acute pancreatitis, though the absolute risk is low. If you've had pancreatitis before, your provider should weigh the benefit-to-risk ratio carefully. Most guidelines recommend monitoring for pancreatitis symptoms (severe abdominal pain radiating to the back, nausea, vomiting) and discontinuing the medication immediately if acute pancreatitis is suspected.
Kidney Disease
GLP-1 medications can cause nausea, vomiting, and diarrhea — especially during the early titration phase. In patients with existing kidney disease, the dehydration caused by these GI side effects can worsen renal function. No dose adjustment is required for mild-to-moderate kidney impairment, but your provider should monitor kidney function more closely and emphasize hydration.
Gallbladder Disease
Rapid weight loss — from any cause — increases the risk of gallstones. GLP-1 medications compound this risk because they produce significant weight loss relatively quickly. If you have a history of gallstones or gallbladder disease, your provider should monitor for symptoms: right upper abdominal pain, especially after fatty meals, nausea, and fever.
Diabetic Retinopathy
In patients with type 2 diabetes, rapid improvements in blood sugar control can temporarily worsen diabetic retinopathy. If you have diabetes and existing eye disease, your provider should coordinate with your ophthalmologist and may proceed more cautiously with dose titration.
Gastroparesis or Severe GI Conditions
GLP-1 medications work partly by slowing gastric emptying — which is exactly the problem in gastroparesis. Patients with existing delayed gastric emptying, inflammatory bowel disease, or severe GERD should discuss these conditions thoroughly with their provider. In some cases, GLP-1 therapy may be possible at lower doses with careful monitoring.
Mental Health Considerations
Eating Disorders
This is a nuanced area that deserves careful thought. GLP-1 medications dramatically reduce appetite, which can be therapeutic for many patients — but could be problematic for someone with a history of anorexia nervosa or other restrictive eating disorders. If you have a current or past eating disorder, your GLP-1 prescriber should be aware and, ideally, coordinating with a mental health professional who specializes in disordered eating.
Depression and Suicidal Ideation
The FDA is currently evaluating post-market reports of suicidal thoughts and behaviors in patients taking GLP-1 medications. Large-scale studies haven't established a causal link, and some research suggests GLP-1 medications may actually improve mood in many patients. However, your provider should ask about your mental health history and monitor for mood changes — especially during the first few months of treatment.
Body Dysmorphia
Rapid weight loss can sometimes exacerbate body image concerns rather than resolve them. A good provider will discuss realistic expectations about physical changes and ensure that your motivation for treatment is health-based rather than driven by dysmorphic thinking.
Embody
Injectable semaglutide with physician oversight
$149 first month, $299/mo after
Paid link · Compounded medications are not FDA-approved and are prepared by licensed pharmacies.
Pregnancy and Fertility
GLP-1 medications are contraindicated during pregnancy. Semaglutide should be stopped at least 2 months before a planned pregnancy; tirzepatide should be stopped at least 1 month before. This is based on animal studies showing potential fetal harm.
There's an important side note: GLP-1 medications can increase fertility by normalizing ovulation in women with PCOS or obesity-related anovulation. If you're of childbearing age and not actively trying to conceive, make sure you're using reliable contraception. Multiple cases of unplanned pregnancies in women on GLP-1 therapy have been documented — sometimes called "Ozempic babies" in the media.
The Screening Your Provider Should Do
At minimum, a responsible GLP-1 prescriber should:
- Ask about personal and family history of thyroid cancer, specifically medullary thyroid carcinoma
- Review your complete medication list for potential interactions
- Check or order baseline labs: thyroid function (TSH), kidney function (eGFR, creatinine), liver enzymes, A1c, and lipid panel
- Screen for history of pancreatitis, gallbladder disease, and gastroparesis
- Ask about eating disorder history and current mental health
- Discuss pregnancy plans if applicable
- Establish a follow-up schedule for monitoring
If a provider prescribes GLP-1 medication without asking about these conditions, that's a red flag. These aren't optional screening steps — they're the standard of care.
Find a Provider Who Screens Thoroughly
Paid links · Compounded medications are not FDA-approved.